乳癌治療市場 - 依治療方式（標靶治療、荷爾蒙治療、化療、免疫治療），全球預測，2023-2032 年

Breast Cancer Therapeutics Market - By Therapy (Targeted Therapy, Hormonal Therapy, Chemotherapy, Immunotherapy), Global Forecast, 2023-2032

出版日期: 2023年11月01日 | 出版商:

Global Market Insights Inc. | 英文 90 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄圖表

在乳癌領域的新事件和強勁的研究與開發的推動下，2023 年至 2032 年間，全球乳癌治療市場的CAGR將達到 7.3%。新興研究揭示了創新療法，推動了對先進治療方案的需求。

例如，2023 年 12 月，在 2023 年聖安東尼奧乳癌研討會 (SABCS) 上，研究重點關注了可改善轉移性乳癌患者預後的研究性治療方法，並深入了解治療抗藥性。其中一項研究HER2CLIMB-02 試驗表明，將圖卡替尼涵蓋曲妥珠單抗emtansine (T-DM1) 治療中可以延長既往接受過治療的HER2 陽性轉移性或局部晚期乳腺癌患者的無進展生存期(PFS)。精準醫學、免疫療法和標靶療法的突破促進了市場成長，滿足了對更有效和個人化乳癌治療不斷成長的需求。隨著科學發現和事件不斷發展的動態格局，市場響應了對乳癌治療改善結果和增強療法的持續追求

乳癌治療市場的總體佔有率根據治療和地區進行分類。

2023年至2032年，化療領域的市場規模將出現顯著的CAGR。儘管標靶治療取得了進步，但化療仍然具有重要意義，特別是在侵襲性癌症類型中。它在新輔助和輔助治療中的作用以及新興的聯合療法維持了需求。透過不斷改進以盡量減少副作用並提高療效，化療保持關鍵地位，滿足不同患者的需求。它在乳癌治療中的持久作用繼續刺激治療市場的需求，確保為患者提供全面的護理和治療選擇。

亞太地區乳癌治療產業從 2023 年到 2032 年將呈現出值得稱讚的CAGR。發病率不斷上升，並且對醫療保健基礎設施的日益關注。隨著亞太地區乳癌發生率激增，人們越來越重視創新療法和先進的治療選擇。隨著醫療保健系統的不斷發展和向個人化醫療的轉變，對標靶治療和尖端治療的需求不斷增加。這個蓬勃發展的市場迎合了該地區對改善結果的追求，在亞太地區的醫療保健領域培育了乳癌治療的動態格局。

例如，2023 年 12 月，輝瑞、莫納什大學和澳洲癌症治療合作研究中心合作發現了一種治療雌激素受體 (ER) 陽性乳癌的潛在臨床前藥物。這項研究揭示了 CTx-648，一種口服生物可利用的「KAT6A/B」抑制劑，顯示出卓越的選擇性和效力。在小鼠模型中，CTx-648 在 ER 陽性乳癌中表現出顯著的抗腫瘤作用，即使在對荷爾蒙治療抗藥性的情況下也是如此。這項突破為針對 KAT6A 治療 ER 陽性乳癌帶來了新的前景，可能為患者提供新的治療途徑。

產業格局
產業影響力
- 成長動力
  - 乳癌負擔日益加重
  - 加大研發投入
  - 啟動多項診斷和篩檢計劃
  - 優惠的保險和報銷政策
- 產業陷阱與挑戰
  - 與乳癌藥物相關的副作用
  - 藥品費用高
- 成長潛力分析
- 透過治療
COVID-19 影響分析
監管環境
波特的分析
PESTEL分析

第 4 章：競爭格局

介紹
公司矩陣分析
主要市場參與者的競爭分析
競爭定位矩陣
戰略儀表板

第 5 章：乳癌治療市場估計與預測：按治療方法，2018-2032 年

主要動力向：透過治療
標靶治療
荷爾蒙療法
化療
免疫療法

第 6 章：乳癌治療市場估計與預測：按地區，2018 - 2032

主要動向：按地區
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 歐洲其他地區
亞太地區
- 中國
- 日本
- 印度
- 澳洲
- 亞太地區其他地區
拉丁美洲
- 巴西
- 墨西哥
- 拉丁美洲其他地區
中東和非洲
- 南非
- 沙烏地阿拉伯
- 中東和非洲其他地區

第 7 章：公司簡介

AstraZeneca plc.
Eli Lilly & Co, Inc.
Pfizer, Inc.
Novartis AG
Amgen
F. Hoffmann La Roche AG
Merck & Co, Inc.
Gilead Sciences, Inc.
Eisai Co., Ltd.
Macrogenics, Inc.
Stemline Therapeutics, Inc.

簡介目錄圖表

Product Code: 466

Global Breast Cancer Therapeutics Market will witness 7.3% CAGR between 2023 and 2032 propelled by novel events and robust research and development within the breast cancer domain. Emerging studies uncover innovative therapies, driving demand for advanced treatment options.

For instance, in December 2023, at the 2023 San Antonio Breast Cancer Symposium (SABCS), research spotlighted investigational treatments offering improved outcomes for metastatic breast cancer patients and insights into treatment resistance. One such research, The HER2CLIMB-02 trial revealed that incorporating tucatinib into trastuzumab emtansine (T-DM1) therapy extended progression-free survival (PFS) among individuals with previously treated HER2-positive metastatic or locally advanced breast cancer. Breakthroughs in precision medicine, immunotherapy, and targeted therapies amplify market growth, meeting the escalating need for more effective and personalized breast cancer treatments. With a dynamic landscape of scientific discoveries and evolving events, the market responds to the continuous quest for improved outcomes and enhanced therapies in the fight against breast cancer

The overall Breast Cancer Therapeutics Market share is classified based on therapy, and region.

The market size from the chemotherapy segment will register a noteworthy CAGR from 2023 to 2032. Despite advancements in targeted therapies, chemotherapy retains its significance, especially in aggressive cancer types. Its role in neoadjuvant and adjuvant settings, alongside emerging combination therapies, sustains demand. With ongoing refinements to minimize side effects and enhance efficacy, chemotherapy maintains a pivotal stance, meeting the needs of diverse patient profiles. Its enduring role in breast cancer treatment continues to fuel demand within the therapeutics market, ensuring comprehensive care and treatment options for patients.

Asia Pacific breast cancer therapeutics industry will showcase a commendable CAGR from 2023 to 2032. rising incidences and a growing focus on healthcare infrastructure. As breast cancer rates surge across Asia Pacific, there's an increased emphasis on innovative therapies and advanced treatment options. With evolving healthcare systems and a shift toward personalized medicine, the demand for targeted therapies and cutting-edge treatments rises. This burgeoning market caters to the region's quest for improved outcomes, fostering a dynamic landscape of breast cancer therapeutics within Asia Pacific's healthcare domain.

For instance, in December 2023, A collaborative effort between Pfizer, Monash University, and the Cancer Therapeutics Cooperative Research Centre, in Australia uncovered a potential pre-clinical drug for Estrogen Receptor (ER) positive breast cancer. This study unveiled CTx-648, an orally bioavailable 'KAT6A/B' inhibitor showing remarkable selectivity and potency. In mouse models, CTx-648 demonstrated significant anti-tumor effects in ER-positive breast cancer, even in cases resistant to hormone therapy. This breakthrough introduces a new prospect for targeting KAT6A in ER-positive breast cancer, potentially offering a novel treatment avenue for patients.

Chapter 1 Methodology & Scope

1.1 Market definition
1.2 Base estimates & calculations
1.3 Forecast Calculation
1.4 Covid-19 impact analysis at global level
1.5 Data validation
1.6 Data sources
- 1.6.1 Primary
- 1.6.2 Secondary
  - 1.6.2.1 Paid sources
  - 1.6.2.2 Public sources

Chapter 2 Executive Summary

2.1 Breast cancer therapeutics industry 360 degree synopsis, 2018 - 2032 (USD Million)
- 2.1.1 Business trends
- 2.1.2 Regional trends
- 2.1.3 Therapy trends

Chapter 3 Breast Cancer Therapeutics Market Insights

3.1 Industry landscape, 2018 - 2032 (USD Million)
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Growing burden of breast cancer
  - 3.2.1.2 Increasing investments in R&D
  - 3.2.1.3 Launch of several diagnostic and screening programs
  - 3.2.1.4 Favorable insurance and reimbursement policies
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 Adverse-effects associated with breast cancer drugs
  - 3.2.2.2 High cost of drugs
- 3.2.3 Growth potential analysis
- 3.2.4 By therapy
3.3 COVID-19 impact analysis
3.4 Regulatory landscape
3.5 Porter's analysis
3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2022

4.1 Introduction
4.2 Company matrix analysis, 2022
4.3 Competitive analysis of major market players, 2022
4.4 Competitive positioning matrix, 2022
4.5 Strategic dashboard, 2022

Chapter 5 Breast Cancer Therapeutics Market Estimates and Forecast, By Therapy, 2018-2032 (USD Million)

5.1 Key trends, by therapy
5.2 Targeted therapy
5.3 Hormonal therapy
5.4 Chemotherapy
5.5 Immunotherapy

Chapter 6 Breast Cancer Therapeutics Market Estimates and Forecast, By Region, 2018 - 2032 (USD Million)

6.1 Key trends, by region
6.2 North America
- 6.2.1 U.S.
- 6.2.2 Canada
6.3 Europe
- 6.3.1 Germany
- 6.3.2 UK
- 6.3.3 France
- 6.3.4 Spain
- 6.3.5 Italy
- 6.3.6 Rest of Europe
6.4 Asia Pacific
- 6.4.1 China
- 6.4.2 Japan
- 6.4.3 India
- 6.4.4 Australia
- 6.4.5 Rest of Asia Pacific
6.5 Latin America
- 6.5.1 Brazil
- 6.5.2 Mexico
- 6.5.3 Rest of Latin America
6.6 Middle East & Africa
- 6.6.1 South Africa
- 6.6.2 Saudi Arabia
- 6.6.3 Rest of Middle East & Africa

Chapter 7 Company Profiles

7.1 AstraZeneca plc.
7.2 Eli Lilly & Co, Inc.
7.3 Pfizer, Inc.
7.4 Novartis AG
7.5 Amgen
7.6 F. Hoffmann La Roche AG
7.7 Merck & Co, Inc.
7.8 Gilead Sciences, Inc.
7.9 Eisai Co., Ltd.
7.10 Macrogenics, Inc.
7.11 Stemline Therapeutics, Inc.

簡介目錄圖表

Data Tables

TABLE 1 Market revenue, by therapy (2022)
TABLE 2 Market share, by region (2022)
TABLE 3 Global breast cancer therapeutics market size, by region, 2018 - 2022 (USD Million)
TABLE 4 Global breast cancer therapeutics market size, by region, 2023 - 2032 (USD Million)
TABLE 5 Global breast cancer therapeutics market size, by therapy, 2018 - 2022 (USD Million)
TABLE 6 Global breast cancer therapeutics market size, by therapy, 2023 - 2032 (USD Million)
TABLE 7 Industry impact forces
TABLE 8 Targeted therapy market size, 2018 - 2022 (USD Million)
TABLE 9 Targeted therapy market size, 2023 - 2032 (USD Million)
TABLE 10 Hormonal therapy market size, 2018 - 2022 (USD Million)
TABLE 11 Hormonal therapy market size, 2023 - 2032 (USD Million)
TABLE 12 Chemotherapy market size, 2018 - 2022 (USD Million)
TABLE 13 Chemotherapy market size, 2023 - 2032 (USD Million)
TABLE 14 Immunotherapy market size, 2018 - 2022 (USD Million)
TABLE 15 Immunotherapy market size, 2023 - 2032 (USD Million)
TABLE 16 North America breast cancer therapeutics market size, by country, 2018 - 2022 (USD Million)
TABLE 17 North America breast cancer therapeutics market size, by country, 2023 - 2032 (USD Million)
TABLE 18 North America breast cancer therapeutics market size, by therapy, 2018 - 2022 (USD Million)
TABLE 19 North America breast cancer therapeutics market size, by therapy, 2023 - 2032 (USD Million)
TABLE 20 U.S. breast cancer therapeutics market size, by therapy, 2018 - 2022 (USD Million)
TABLE 21 U.S. breast cancer therapeutics market size, by therapy, 2023 - 2032 (USD Million)
TABLE 22 Canada breast cancer therapeutics market size, by therapy, 2018 - 2022 (USD Million)
TABLE 23 Canada breast cancer therapeutics market size, by therapy, 2023 - 2032 (USD Million)
TABLE 24 Europe breast cancer therapeutics market size, by country, 2018 - 2022 (USD Million)
TABLE 25 Europe breast cancer therapeutics market size, by country, 2023 - 2032 (USD Million)
TABLE 26 Europe breast cancer therapeutics market size, by therapy, 2018 - 2022 (USD Million)
TABLE 27 Europe breast cancer therapeutics market size, by therapy, 2023 - 2032 (USD Million)
TABLE 28 Germany breast cancer therapeutics market size, by therapy, 2018 - 2022 (USD Million)
TABLE 29 Germany breast cancer therapeutics market size, by therapy, 2023 - 2032 (USD Million)
TABLE 30 UK breast cancer therapeutics market size, by therapy, 2018 - 2022 (USD Million)
TABLE 31 UK breast cancer therapeutics market size, by therapy, 2023 - 2032 (USD Million)
TABLE 32 France breast cancer therapeutics market size, by therapy, 2018 - 2022 (USD Million)
TABLE 33 France breast cancer therapeutics market size, by therapy, 2023 - 2032 (USD Million)
TABLE 34 Spain breast cancer therapeutics market size, by therapy, 2018 - 2022 (USD Million)
TABLE 35 Spain breast cancer therapeutics market size, by therapy, 2023 - 2032 (USD Million)
TABLE 36 Italy breast cancer therapeutics market size, by therapy, 2018 - 2022 (USD Million)
TABLE 37 Italy breast cancer therapeutics market size, by therapy, 2023 - 2032 (USD Million)
TABLE 38 Rest of Europe breast cancer therapeutics market size, by therapy, 2018 - 2022 (USD Million)
TABLE 39 Rest of Europe breast cancer therapeutics market size, by therapy, 2023 - 2032 (USD Million)
TABLE 40 Asia Pacific breast cancer therapeutics market size, by country, 2018 - 2022 (USD Million)
TABLE 41 Asia Pacific breast cancer therapeutics market size, by country, 2023 - 2032 (USD Million)
TABLE 42 Asia Pacific breast cancer therapeutics market size, by therapy, 2018 - 2022 (USD Million)
TABLE 43 Asia Pacific breast cancer therapeutics market size, by therapy, 2023 - 2032 (USD Million)
TABLE 44 China breast cancer therapeutics market size, by therapy, 2018 - 2022 (USD Million)
TABLE 45 China breast cancer therapeutics market size, by therapy, 2023 - 2032 (USD Million)
TABLE 46 Japan breast cancer therapeutics market size, by therapy, 2018 - 2022 (USD Million)
TABLE 47 Japan breast cancer therapeutics market size, by therapy, 2023 - 2032 (USD Million)
TABLE 48 India breast cancer therapeutics market size, by therapy, 2018 - 2022 (USD Million)
TABLE 49 India breast cancer therapeutics market size, by therapy, 2023 - 2032 (USD Million)
TABLE 50 Australia breast cancer therapeutics market size, by therapy, 2018 - 2022 (USD Million)
TABLE 51 Australia breast cancer therapeutics market size, by therapy, 2023 - 2032 (USD Million)
TABLE 52 Rest of Asia Pacific breast cancer therapeutics market size, by therapy, 2018 - 2022 (USD Million)
TABLE 53 Rest of Asia Pacific breast cancer therapeutics market size, by therapy, 2023 - 2032 (USD Million)
TABLE 54 Latin America breast cancer therapeutics market size, by country, 2018 - 2022 (USD Million)
TABLE 55 Latin America breast cancer therapeutics market size, by country, 2023 - 2032 (USD Million)
TABLE 56 Latin America breast cancer therapeutics market size, by therapy, 2018 - 2022 (USD Million)
TABLE 57 Latin America breast cancer therapeutics market size, by therapy, 2023 - 2032 (USD Million)
TABLE 58 Brazil breast cancer therapeutics market size, by therapy, 2018 - 2022 (USD Million)
TABLE 59 Brazil breast cancer therapeutics market size, by therapy, 2023 - 2032 (USD Million)
TABLE 60 Mexico breast cancer therapeutics market size, by therapy, 2018 - 2022 (USD Million)
TABLE 61 Mexico breast cancer therapeutics market size, by therapy, 2023 - 2032 (USD Million)
TABLE 62 Rest of Latin America breast cancer therapeutics market size, by therapy, 2018 - 2022 (USD Million)
TABLE 63 Rest of Latin America breast cancer therapeutics market size, by therapy, 2023 - 2032 (USD Million)
TABLE 64 Middle East & Africa breast cancer therapeutics market size, by country, 2018 - 2022 (USD Million)
TABLE 65 Middle East & Africa breast cancer therapeutics market size, by country, 2023 - 2032 (USD Million)
TABLE 66 Middle East & Africa breast cancer therapeutics market size, by therapy, 2018 - 2022 (USD Million)
TABLE 67 Middle East & Africa breast cancer therapeutics market size, by therapy, 2023 - 2032 (USD Million)
TABLE 68 South Africa breast cancer therapeutics market size, by therapy, 2018 - 2022 (USD Million)
TABLE 69 South Africa breast cancer therapeutics market size, by therapy, 2023 - 2032 (USD Million)
TABLE 70 Saudi Arabia breast cancer therapeutics market size, by therapy, 2018 - 2022 (USD Million)
TABLE 71 Saudi Arabia breast cancer therapeutics market size, by therapy, 2023 - 2032 (USD Million)
TABLE 72 Rest of Middle East & Africa breast cancer therapeutics market size, by therapy, 2018 - 2022 (USD Million)
TABLE 73 Rest of Middle East & Africa breast cancer therapeutics market size, by therapy, 2023 - 2032 (USD Million)